[{"address1": "50 Broadway", "address2": "7th Floor", "city": "London", "zip": "SW1H 0DB", "country": "United Kingdom", "phone": "44 20 7400 3347", "website": "https://roivant.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.", "fullTimeEmployees": 908, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew  Gline", "age": 39, "title": "CEO & Director", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 738189, "exercisedValue": 0, "unexercisedValue": 56042228}, {"maxAge": 1, "name": "Dr. Mayukh  Sukhatme M.D.", "age": 47, "title": "President, Chief Investment Officer & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 574560, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard  Pulik", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 2288638, "exercisedValue": 0, "unexercisedValue": 4094954}, {"maxAge": 1, "name": "Ms. Rakhi  Kumar", "age": 43, "title": "Chief Accounting Officer", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 2045998, "exercisedValue": 0, "unexercisedValue": 1565874}, {"maxAge": 1, "name": "Dr. Eric  Venker M.D., Pharm.D.", "age": 36, "title": "President & COO", "yearBorn": 1987, "fiscalYear": 2023, "totalPay": 1281230, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Drew  Kramer", "title": "Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Josh  Chen", "title": "General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kelly  Graff", "title": "Head of People", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alex  Gasner", "title": "Executive Vice President of Roivant Health", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matt  Maisak", "title": "Chief Operating Officer of Roivant Platforms", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 4, "overallRisk": 7, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 11.37, "open": 11.37, "dayLow": 11.18, "dayHigh": 11.41, "regularMarketPreviousClose": 11.37, "regularMarketOpen": 11.37, "regularMarketDayLow": 11.18, "regularMarketDayHigh": 11.41, "beta": 1.255, "trailingPE": 1.9685863, "forwardPE": -9.322313, "volume": 5653939, "regularMarketVolume": 5653939, "averageVolume": 6235877, "averageVolume10days": 12898070, "averageDailyVolume10Day": 12898070, "bid": 11.27, "ask": 11.3, "bidSize": 5300, "askSize": 5300, "marketCap": 8415759872, "fiftyTwoWeekLow": 8.245, "fiftyTwoWeekHigh": 13.055, "priceToSalesTrailing12Months": 53.16235, "fiftyDayAverage": 11.4956, "twoHundredDayAverage": 11.04675, "currency": "USD", "enterpriseValue": 3502327296, "profitMargins": 29.91756, "floatShares": 363164377, "sharesOutstanding": 739521984, "sharesShort": 33566376, "sharesShortPriorMonth": 40904604, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.0454, "heldPercentInsiders": 0.29094, "heldPercentInstitutions": 0.7487, "shortRatio": 6.77, "shortPercentOfFloat": 0.0602, "impliedSharesOutstanding": 746078016, "bookValue": 7.354, "priceToBook": 1.533859, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": 4736038912, "trailingEps": 5.73, "forwardEps": -1.21, "enterpriseToRevenue": 22.124, "enterpriseToEbitda": -3.444, "52WeekChange": 0.08149564, "SandP52WeekChange": 0.34083736, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ROIV", "underlyingSymbol": "ROIV", "shortName": "Roivant Sciences Ltd.", "longName": "Roivant Sciences Ltd.", "firstTradeDateEpochUtc": 1607437800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9d037e9b-5cb8-3bad-8efe-5f0e5f374cbd", "messageBoardId": "finmb_282015801", "gmtOffSetMilliseconds": -14400000, "currentPrice": 11.28, "targetHighPrice": 22.0, "targetLowPrice": 12.5, "targetMeanPrice": 17.06, "targetMedianPrice": 17.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 5678514176, "totalCashPerShare": 7.679, "ebitda": -1016824000, "totalDebt": 379057984, "quickRatio": 27.407, "currentRatio": 27.908, "totalRevenue": 158303008, "debtToEquity": 6.43, "revenuePerShare": 0.204, "returnOnAssets": -0.15028, "returnOnEquity": 1.2771499, "freeCashflow": -645150656, "operatingCashflow": -708164992, "revenueGrowth": 1.55, "grossMargins": -2.30591, "operatingMargins": -4.0244, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-03"}]